However, our findings suggest that dual PPARα/γ agonist tesaglitazar inhibits the development of NAFLD and atherosclerosis in a diabetic mouse model by regulating glucose and lipid metabolism, and the inflammatory response. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.